GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » Interest Coverage

RNXT (RenovoRx) Interest Coverage : N/A (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is RenovoRx Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. RenovoRx's Operating Income for the three months ended in Mar. 2025 was $-3.11 Mil. RenovoRx's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. RenovoRx Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for RenovoRx's Interest Coverage or its related term are showing as below:


RNXT's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 117.6
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


RenovoRx Interest Coverage Historical Data

The historical data trend for RenovoRx's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

RenovoRx Interest Coverage Chart

RenovoRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
Get a 7-Day Free Trial - - No Debt - N/A

RenovoRx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt N/A N/A

Competitive Comparison of RenovoRx's Interest Coverage

For the Biotechnology subindustry, RenovoRx's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovoRx's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Interest Coverage distribution charts can be found below:

* The bar in red indicates where RenovoRx's Interest Coverage falls into.


;
;

RenovoRx Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RenovoRx's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, RenovoRx's Interest Expense was $0.00 Mil. Its Operating Income was $-10.97 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.21 Mil.

GuruFocus does not calculate RenovoRx's interest coverage with the available data.

RenovoRx's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, RenovoRx's Interest Expense was $0.00 Mil. Its Operating Income was $-3.11 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.19 Mil.

GuruFocus does not calculate RenovoRx's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


RenovoRx  (NAS:RNXT) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


RenovoRx Interest Coverage Related Terms

Thank you for viewing the detailed overview of RenovoRx's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovoRx Business Description

Traded in Other Exchanges
N/A
Address
2570 West El Camino Real, Suite 320, Mountain View, CA, USA, 94040
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Executives
Shaun Bagai director, officer: Chief Executive Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Ramtin Agah director, officer: Chief Medical Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Laurence Marton director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Angela Nelms officer: Chief Operating Officer C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers officer: Chief Financial Officer 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Bank Of The West 10 percent owner PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Kirsten Angela Macfarlane director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman officer: Chief Financial Officer 65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners officer: Chief Financial Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303